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INTRODUCTION
Since the first reported cases of food-borne botulism in the
late 18th century, botulism has gained attention not only as a
threat to food producers and consumers but also as a potential
cause of crib death of small babies, as a deadly trip for intra-
venous drug abusers, and as an inspiration for bioterrorists.
Botulism is caused by botulinum toxins, which are highly po-
tent neurotoxins formed during the growth of the spore-form-
ing bacterium Clostridium botulinum.
Based on the serological properties of the toxins they pro-
duce, C. botulinum strains are divided into toxinotypes A to G.
Noteworthy of the bacterial species C. botulinum is its old-
fashioned taxonomy; the only common denominator of all C.
botulinum strains is the ability to produce neurotoxins that
cause flaccid paralysis. C. botulinum strains form four geno-
typically and phenotypically distinct groups of organisms, des-
ignated I to IV (100, 107, 196). Generally, groups I and II cause
botulism in humans, while group III is involved with animal
botulism, but exceptions occur. Group IV has not generally
been associated with illness. Based on its phenotypic and ge-
netic traits, group IV C. botulinum has been proposed to be
renamed Clostridium argentinense (203). Of the human patho-
genic strains, group I cultures produce toxin A, B, or F and
group II cultures produce toxin B, E, or F. Dual-toxin-produc-
ing strains have also been reported (72, 80, 121), as have those
producing only one type of toxin but carrying a silent gene for
another (73, 74, 121). Other clostridia, namely, C. butyricum
and C. baratii, are also known to produce type E and F toxins,
respectively.
Phenotypically, group I and II C. botulinum strains differ
from each other significantly. Group I organisms seem to be
more of terrestrial origin and are present in temperate cli-
mates, whereas group II strains, particularly type E, are
frequently found in aquatic environments in the Northern
hemisphere (Table 1). Differences in spore heat resistance
and growth temperatures are responsible for the safety risks
posed by C. botulinum groups I and II in the food industry;
group I spores, which have a high heat resistance (112, 138,
180, 184, 192, 202), cause problems in canning and home
preservation of vegetables and meat, whereas group II
spores, with somewhat lower spore heat resistance (135, 140,
168–170), are of great concern in minimally processed pack-
aged foods that have extended shelf lives at refrigerated
temperatures (134, 167).
Botulinum neurotoxins are 150-kDa proteins with zinc-endo-
peptidase activity (155). The toxin molecule is secreted as a
progenitor toxin that contains the neurotoxin as well as non-
* Corresponding author. Mailing address: Department of Food and
Environmental Hygiene, University of Helsinki, P.O. Box 66, 00014
University of Helsinki, Finland. Phone: 358-9-191 57107. Fax: 358-9-
191 57101. E-mail: miia.lindstrom@helsinki.fi.
298
toxic components. The nontoxic components protect the neu-
rotoxin from environmental stress and assist in absorption of
the neurotoxin into the body (77). The neurotoxin molecule
consists of two subunits: a 100-kDa heavy chain, which is re-
sponsible for the binding and translocation of the toxin across
the synaptic membrane through specific receptors, and a 50-
kDa light chain, which cleaves the proteins involved in acetyl-
choline vesicle docking and fusion to the presynaptic mem-
brane (156). Inhibition of the neurotransmitter release causes
paralysis of the corresponding muscle. The maximal potency of
the botulinum neurotoxins is achieved only after enzymatic
activation of the toxin molecule. This has been suggested to be
at least partly related to cleavage of the toxin molecule (45,
165). Generally, in proteolytic group I C. botulinum this is done
by endogenous enzymes of the organism, but neurotoxins pro-
duced by nonproteolytic group II strains may require external
proteases, such as trypsin (45, 55), for activation.
Typical of botulism is a descending flaccid paralysis that,
unless treated immediately and appropriately, may lead to
death when the respiratory musculature fails. Food-borne bot-
ulism, the most well-known form of botulism, is an intoxication
that follows when food containing preformed botulinum neu-
rotoxin is ingested. Other significant forms of botulism are
infections that result from toxin formation from spores in vivo.
The most common of these is infant botulism, where botulinal
spores germinate, grow, and subsequently produce toxin in the
gastrointestinal lumens of small babies, in whom the normal
gut microflora is poorly developed (14).
Since botulism is a life-threatening condition, a rapid diag-
nosis is essential. This challenges not only the awareness of the
disease by clinicians but also the laboratory diagnostics. Apart
from the ultimate goal of rapid diagnosis and, above all, saving
the patient, every attempt to increase our understanding of the
epidemiology of botulism should be made. This enables the
future development of prevention strategies against the dis-
ease. In addition to the detection of botulinum toxin and C.
botulinum in the patient, the diagnostics should aim at physi-
ological and genetic typing of the disease isolates. In the fol-
TABLE 1. Characteristics of Clostridium botulinum groups I and II
Characteristic C. botulinum group I C. botulinum group II Reference(s)
Toxinotypes A, AB, B, BF, F B, E, F 197
Strain origin Soil Aquatic environments 34, 98, 106, 123, 126, 151,
194, 195, 208, 220, 222
Genome size (Mbp) 3.9–4.1 3.6–4.1 96, 130
GC content (%) of genome 26–28 26–28 115, 127, 128
Genetic diversity Narrow Wide 96, 110, 130, 159, 160
Utilization of proteins as
energy source
Yes No 35
Carbohydrate fermentation Glucose, fructose, maltose,
salicin, sorbitol
Amygdalin, dextrin, fructose, galactose,
glucose, glycogen, maltose, mannose,
melezitose, ribose, sorbitol, starch,
sucrose, trehalose
35, 132, 197
Metabolite production Acetic, butyric, isobutyric,
isovaleric, isocaproic, propionic,
and valeric acids; alcohols;
hydrogen sulfide
Acetic, butyric, formic, succinic, and
lactic acids
197
Bacteriocin production Boticin NRa 51, 125
Colony morphology on
blood agar
2—6 mm (diam); irregular margin;
opaque, raised center; narrow
hemolysis
1–3 mm (diam); slightly irregular with
lobate margins; translucent to
semiopaque with matt surface;
mosaic structure in oblique light;
narrow hemolysis
35, 197
Colony morphology on egg yolk
agar (lipase reaction)
Iridescent layer on and
around colonies
Iridescent layer on and
around colonies
197
Susceptibility to antibioticsb Susceptible to erythromycin,
metronidazole, penicillin,
rifampin, tetracycline; resistant
to cycloserine, gentamicin,
nalidixic acid, sulfamethoxazole,
trimethoprim
Susceptible to erythromycin,
metronidazole, penicillin, rifampin,
chloramphenicol, clindamycin,
tetracycline, trimethoprim; resistant
to gentamicin, nalidixic acid,
cephalotin, sulfamethoxazole
204
Minimum/optimum growth
temp (°C)
10/35–37 3/26–30 56, 57, 83, 139, 180, 181,
197, 202
Growth-limiting pH 4.3–4.5 5.0–5.1 185, 193
Growth-limiting NaCl in water
phase (%)
10 5 197
Heat resistance of spores High (D121–110°C,
c 0.15–1.8 min) Moderate (D85°C,
c 1–98 min) 112, 135, 139, 140, 168–170,
184, 192
Typical vehicle foods for
botulism
For food-borne botulism,
vegetables, meat, and canned
foods; for infant botulism, honey
For food-borne botulism, fish, meat,
and minimally processed packaged
foods; for infant botulism, NR
93a, 134
a NR, not reported.
b Based on information on C. botulinum type A and E strains (204).
c DT, decimal reduction time at temperature T.
VOL. 19, 2006 LABORATORY DIAGNOSTICS OF BOTULISM 299
lowing we review the current status of the laboratory diagnos-
tics of human botulism.
HUMAN BOTULISM
Botulism is a potentially lethal condition caused by botuli-
num neurotoxin. The neurotoxin can enter the body via the
gastrointestinal tract or through mucous membranes of, for
instance, the eyes or the respiratory tract. Toxin production
from otherwise harmless C. botulinum, C. butyricum, or C.
baratii spores may also occur in vivo. After entering the body,
the neurotoxin is absorbed into the blood and lymphatic cir-
culation, which then mediate the toxin to motor nerve endings
where it blocks the neurotransmitter release. Typical clinical
symptoms of all forms of botulism include cranial muscle pa-
ralysis, such as double vision and dilated pupils, slurred speech,
dry mouth, difficulty in swallowing and speaking, and facial
paralysis. As the disease progresses, paralysis of the limbs and
respiratory dysfunction become apparent. Respiratory muscle
paralysis can lead to death. Recovery occurs upon the sprout-
ing of transitory nerve endings that reside when the synaptic
activity of the original nerve regenerates (148). Recovery time
may be several weeks to months and is dependent on the
amount of toxin ingested and, to a lesser extent, on the toxin
type in question. Type A toxin tends to be more potent than
types B and E and causes the longest-lasting disease (71).
Food-Borne Botulism
The classical form of botulism is food poisoning, an intoxi-
cation that follows the consumption of food containing pre-
formed neurotoxin. Depending on the toxic dose, the incuba-
tion period may vary from 12 to 72 h. In addition to the general
signs of botulism, the food-borne form may be manifested by
gastrointestinal symptoms such as nausea, vomiting, and con-
stipation. The treatment consists mainly of intensive symptom-
atic care, including respiratory support (24). Intravenous ad-
ministration of specific trivalent antitoxin towards A, B, and E
toxins may be used to neutralize the circulating toxin. How-
ever, the success of the antitoxin treatment is strongly depen-
dent on the time of administration; if the toxin has entered the
nerve endings and disappeared from blood circulation, the
treatment will be irrelevant. Furthermore, due to the risk of
severe allergic reactions to the antiserum, it is no longer used
in some countries (25).
Typical differential diagnoses include Guillain-Barre´ syn-
drome, Miller-Fisher syndrome, chemical intoxication, stroke,
and staphylococcal food poisoning (36, 105). Suspected drug
and alcohol abuse may occasionally prolong the time for a
diagnosis to be made.
Compared with food-borne illness or death due to more
common pathogens, such as Campylobacter, Salmonella, and
Clostridium perfringens, food-borne botulism outbreaks are rel-
atively rare. However, regions with a high incidence of botu-
lism that causes a considerable public health hazard include
the Republic of Georgia, Poland, China, Russia, Kyrgyzstan,
and certain ethnic populations in the North, e.g., Alaskan
Inuits. Japan, Italy, Portugal, Germany, France, and the
former Yugoslavia have also reported high numbers of cases.
The foods most frequently involved, if traced, are home-pre-
pared items such as cured meats, canned vegetables, and fer-
mented fish products. These outbreaks are usually sporadic
and restricted to a family. Commercial foods have less fre-
quently been involved in food-borne botulism, but such out-
breaks may be large, and they cause significant economic losses
to the food industry (134).
The case-fatality rate of food-borne botulism in developed
countries is 5 to 10% (199). Worldwide, more than half of the
cases (52%) were due to type B toxin, with types A and E
accounting for 34% and 12%, respectively, in 1995 (91). On
rare occasions, type F toxin has been associated with food-
borne botulism (90). Apart from the type of toxin causing the
outbreaks, no information on the physiologic group of C. bot-
ulinum type B or F strains involved is usually provided.
Infant Botulism
Unlike food-borne botulism, the other forms of human bot-
ulism are actually infections where the toxigenesis occurs in
vivo. Infectious botulism is related mainly to group I C. botu-
linum, as its temperature optimum for growth and subsequent
toxin production is close to the body temperature, while the
growth of group II organisms at the same temperature is lim-
ited (197). For infant botulism (150, 172), in addition to group
I C. botulinum types A and B (92, 93), Bf (21), and F (99), cases
due to type E and F toxins produced by Clostridium butyricum
(18, 92, 144) and Clostridium baratii (22, 88, 119), respectively,
have been reported. Infant botulism typically affects babies
under 1 year of age, with the youngest reported patient being
only 54 h old (22, 119). The condition develops as a conse-
quence of ingesting spores of toxin-producing clostridia (9). As
the gut microflora of small babies is poorly developed, C.
botulinum spores may germinate and form a toxin-producing
culture in the intestine. The clinical manifestation of infant
botulism varies from a subclinical condition to sudden death
(12). It often starts with constipation that can last for several
days, followed by the distinctive flaccid paralysis manifested by
impaired feeding due to muscle weakness in the mouth and
throat, facial muscle paralysis, ptosis, and general weakness
(10). Infant botulism has been suggested to be a causative
agent of crib death (6, 14).
The main treatment for infant botulism is high-quality sup-
portive care, with special attention focused on the patient’s
nutrition and respiratory functions (13, 116). The use of anti-
toxin is often not required (13), and the case-fatality rate is less
than 2% (39). However, since 2003 a human-derived immune
globulin (75) has been available in the United States and has
been shown to significantly shorten the hospitalization period
and decrease the treatment costs (209). The only foodstuffs
that have been associated with infant botulism are honey (19),
which may carry high numbers of C. botulinum spores (11, 52,
158, 159), and infant milk powder (29). Dust and other mate-
rials in the environment also seem to be important sources of
spores (11, 52a, 161).
Wound Botulism
Wound botulism is a rare form of botulism, although it is
increasingly diagnosed among injecting drug abusers due to
the use of contaminated needles or impure heroin (3, 16, 17,
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157, 166, 213). Wound botulism follows when C. botulinum
spores germinate and grow in profound wounds or abscesses
that provide anaerobic conditions. The clinical outcome is sim-
ilar to the food-borne form, albeit with an absence of gastro-
intestinal signs. Wound botulism is often accompanied by a
mixed infection and may be due to more than one botulinum
toxin-producing strain (3). The median incubation period is
7 days. In addition to respiratory support, the treatment of
wound botulism includes thorough surgical debridement, an-
tibiotics, and the administration of antitoxin. The estimated
case-fatality rate is 15% (91).
Infectious Botulism in Adults
The adult form of infectious botulism is rare and resembles
infant botulism in its pathogenesis and clinical status. It results
from colonization of the intestinal tract by toxin-producing clos-
tridia (40, 64, 143, 145). People with altered intestinal flora due to
abdominal surgery (76, 111), prolonged antimicrobial treatment,
or gastrointestinal wounds and abscesses are particularly vulner-
able (40). Infectious botulism in adults is distinguished from the
food-borne form by a different history of food consumption, with
a missing association to foods with high risk of botulism (143).
Other Forms of Botulism
Inhalation botulism may result from aerosolization of the
neurotoxin. A few human cases have been reported (101).
Iatrogenic botulism with local or generalized weakness is rare
but can develop as a consequence of therapeutic injection of
the neurotoxin (20, 149). A distinctive “outbreak” of iatrogenic
botulism due to maladroit botulinum toxin treatment caused
botulism in four people in Florida in November 2004 (7).
LABORATORY DIAGNOSTICS OF BOTULISM
As botulism is a life-threatening condition, a rapid diagnosis is
required for successful therapy. Apart from the clinical manifes-
tation and patient history, the diagnosis is based on positive lab-
oratory findings. Of these, detection of toxin in the patient’s se-
rum and/or feces remains the standard method (118) (Fig. 1). The
detection of C. botulinum in patient samples, such as feces, gastric
and intestinal contents, and wound swabs and tissues, supports
the diagnosis (3, 39, 118, 162), but should not exclusively be
considered pathognomonic of the disease. Sometimes the pres-
ence of several toxin-producing strains may complicate the diag-
nostics (3, 29, 131). In some cases of infant botulism, the presence
of C. botulinum alone in the feces or intestinal content of the
patient may be sufficient for diagnosis even if the neurotoxin
could not be detected in samples from the patient (38).
Whereas a rapid diagnosis of botulism is a prerequisite for
the patient to survive and recover, a more thorough investiga-
tion of botulism outbreaks is needed to provide epidemiolog-
ical information about the disease (Fig. 1). This includes the
isolation of C. botulinum from the patient and from vehicle
foods or other sources of spores or toxin and genotypic analysis
(see below) of the disease isolates. Furthermore, characteriza-
tion of the physiological group of these isolates is fundamental
to improve our knowledge of the risk factors for and preven-
tion strategies against different forms of botulism.
In the following we discuss the problems and developments
in the laboratory diagnostic tools and procedures established
for investigation of human botulism.
Laboratory Safety
The extreme potency of botulinum neurotoxin necessitates
rigid requirements to ensure the safety of laboratory workers.
Despite the potency of its neurotoxin, the noninvasive and
noncontagious C. botulinum has been graded as a class II
pathogen. Appropriate biosafety level 2 containment facilities
and trained personnel are therefore a minimum requirement
for work with C. botulinum. Additional contingencies should
be considered whenever aerosol or droplet formation from
toxic materials is expected. As the neurotoxins form a potential
FIG. 1. Laboratory diagnostics of botulism. The standard methods are
marked with black arrows, and methods aiming at rapid initial screening
are marked with gray arrows. Measures aiming at the characterization of
the disease isolates and providing complete epidemiological information
are marked with white arrows. TPGY, tryptone-peptone-glucose-yeast
extract medium; CMM, cooked-meat medium; CBI, C. botulinum isola-
tion medium.
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threat for bioterrorism, restricted entrance to the laboratory
facilities containing toxic cultures is a necessity. The definition
of additional contingency measures should be based on a thor-
ough risk assessment of activities in each laboratory handling
C. botulinum and its toxin. The efficacy of the pentavalent
toxoid formerly used to immunize laboratory staff worldwide
has been shown to be lower than expected (Centers for Disease
Control and Prevention, unpublished data). Therefore, careful
attention needs to be paid to the everyday safety of the labo-
ratory staff. Attempts to develop new vaccines against botulism
are being made both in the United States and in Europe (24).
Detection of Botulinum Neurotoxin
While the mouse lethality assay has remained the standard
test for the detection of botulinum neurotoxins, there has been
tremendous progress in the development of alternative tests
during the past decade (Table 2) (188). The latest advances in
assay development have successfully aimed at rapidity and
sensitivity; the fastest tests are now performed in 20 min, and
the test sensitivities have surpassed that of the mouse bioassay.
However, further research is warranted to gain speed and
sensitivity with a single test that would optimally detect all
seven neurotoxin types simultaneously. Furthermore, many of
the recently developed test systems have been targeted to the
medical industry for testing the potencies of therapeutic prep-
arations of purified botulinum toxins, and validations on foods
or clinical materials have not been done. Components of com-
plex matrices, such as feces, blood, pus, and foods, may inter-
fere with test reactions, and high concentrations of competitive
microbes in many sample materials can retard the growth of
and toxin production by C. botulinum. Fecal proteinases may
degrade botulinum toxin, causing false-negative results. There-
fore, there is a need for systematic validation of botulinum
toxin detection tests in clinical sample materials and foods.
Mouse lethality assay. The standard procedure for the de-
tection of botulinum toxin is the mouse lethality assay (162,
201). The test is based on an intraperitoneal injection into
laboratory mice of sample diluted in phosphate buffer. If the
sample contains toxin, the mice develop typical signs of botu-
lism, including fuzzy hair, muscle weakness, and respiratory
failure that manifests as a wasp-like narrowed waist. These
symptoms usually develop within a day postinjection (39) but
may take several days to appear. The nascent toxin becomes
active only when cleaved (55), so toxins from strains of group
II C. botulinum require trypsin activation before analysis, as
these strains lack the required proteolytic activity.
The toxin type is determined by neutralization of the toxin
with specific antitoxins (37). Briefly, mice injected with the
neutralizing antitoxin survive, while the others develop botu-
lism. Alternatively, the sample eluate may be treated with
antitoxins before administration to mice. While the method is
very specific, any of the seven toxin types can be identified. The
mouse bioassay is very sensitive, with one intraperitoneal
mouse 50% lethal dose corresponding to 5 to 10 pg (197) and
the detection limit being 0.01 ng/ml of sample eluate (216). In
clinical microbiological laboratories, the assay has been used
with fecal, serum, gastric, wound, and food samples as well as
supernatants from bacterial cultures. However, the assay is
laborious and expensive and naturally presents an ethical di-
lemma due to the use of laboratory animals. Only a limited
number of laboratories worldwide perform the mouse bioas-
say. In suspected clinical cases of botulism where immediate
treatment is required, the mouse assay may also be too slow to
make a diagnosis. False-positive test results due to in vivo toxin
formation from a high number (107) of C. botulinum spores
(154), endotoxins from gram-negative bacteria (200), and tet-
anus toxin (197) have been reported.
Nonlethal mouse assay. Another type of mouse assay with a
more humane endpoint of local muscle paralysis as a result of
subcutaneous injection of botulinum toxin type A has been
explored for testing the potency of botulinum neurotoxins for
therapeutic use (186). The nonlethal mouse assay is equal to
the conventional bioassay in sensitivity and specificity, but it
does not cause signs of distress or impaired movements in the
animals (186). However, the assay has been targeted to po-
tency testing of purified neurotoxins, and thus it has not been
validated for microbiological laboratories investigating com-
plex sample matrices.
Immunological methods. A wealth of immunoassay formats
for the detection of botulinum neurotoxins have been re-
ported. Compared with the mouse test, the immunoassays are
technically simple and fast to perform and interpret (58). Al-
though many of the earliest assays, such as radioimmunoassay
(15, 23), gel diffusion assay (69, 152, 210), passive hemagglu-
tination assay (114), and the early applications of enzyme-
linked immunosorbent assay (ELISA) (47, 164, 177) have poor
sensitivities or specificities, the recent developments in signal
amplification have enabled sensitivities equal to that of the
mouse bioassay (Table 2). A drawback with immunological
tests is that high-quality antibodies are not generally available.
In addition to biologically active neurotoxins, inactivated toxin
(e.g., after a heat treatment) may cause false-positive results.
Furthermore, genetic variation within the different serotypes
of the neurotoxin may result in decreased affinity to monoclo-
nal antibodies, causing false-negative results (198).
ELISA is by far the most commonly applied immunoassay
format in the detection of botulinum neurotoxins. Briefly, the
neurotoxin in a sample binds to a solid test matrix that is
usually precoated with polyclonal or monoclonal capture anti-
bodies against one or more toxins (sandwich ELISA) (47, 164).
A second toxin antibody is then used to bind the toxin. Finally,
an antiantitoxin molecule, carrying an enzyme such as alkaline
phosphatase or horseradish peroxidase, is used to produce a
signal through enzymatic cleavage of a chromogenic substrate.
The sensitivity of the conventional ELISAs for botulinum neu-
rotoxin detection is some 10- to 100-fold lower than that of the
mouse bioassay (47, 164, 174, 177) (Table 2). Signal amplifi-
cation using a chromogenic diaphorase system (189), biotiny-
lated antibodies and avidin-enzyme conjugate (66, 68), or en-
zyme-linked coagulation assay (ELCA) (53, 54, 178) has enabled
increased assay sensitivity.
ELISAs have been extensively tested with purified botuli-
num toxin (60, 173, 206), toxic C. botulinum cultures (47, 48,
60, 70, 164, 189), and foods related to botulism outbreaks (67,
68) or artificially contaminated with botulinum toxin or C.
botulinum (174, 177, 189). A collaborative study in 11 labora-
tories showed high reproducibility of an amplified ELISA with
foods containing botulinum toxins (70). Food components
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TABLE 2. Diagnostic assays applied in the detection of botulinum neurotoxins
Assay Time toperform
Type of
toxins Detection limit Application(s) Special feature(s)
a Reference(s)
Mouse lethality assay 1–4 daysb A, B, C, D,
E, F, G
20–30 pg/ml,
1 MLD/ml
Bacterial cultures, serum,
feces, gastric contents,
foods, environmental
samples
Standard method 39, 162
ELISA 1–2 days A 10 MLD50 Inoculated beans and
mushrooms
Polyclonal (horse) Ab as CA 177
8 h A 4–8 pg/ml, 1–2
MLD/ml
Toxin potency testing in the
medical industry
Monoclonal (BA93) and
polyclonal (rabbit) Ab as CA
60
8 h A, B NRc Fecal samples related to
infant botulism cases
Polyvalent, polyclonal (burro)
Ab as CA
49
8 h A, B 0.2 ng/ml Human serum Polyclonal (horse) Ab as CA 206
8 h E, F 0.5–2 ng/ml Human serum Polyclonal (horse) Ab as CA 173
8 h A, B, E 9–45 pg Inoculated ground
turkey meat
Polyvalent, polyclonal (horse) Ab
as CA
174
Amplified ELISA 8 h A 5–10 MLD50 Inoculated canned salmon
and corned beef
Monoclonal antibody (BA11),
diaphorase-based
amplification system
189
8 h A 10 MLD/ml Bacterial culture from cheese
related to botulism
outbreak
Polyclonal (goat) Ab,
diaphorase-based
amplification system
66
8 h A, B, E, F 1–10 MLD,
0.2–1 ng/ml
Chili and potato linked to
botulism outbreak
Polyclonal (goat/rabbit) Ab as
CA, biotin-streptavidin-based
amplification system
67, 68
ELISA-ELCA 5 h E 1 MLD Inoculated fish Polyclonal (chicken) Ab as CA 178
1–2 days A, B, E 5–10 pg/ml,
1 MLD
Bacterial cultures Polyclonal (chicken/horse serum)
Ab as CA
53, 54
Immuno-PCR 8 h A 5 pg Purified toxin Monoclonal antibody (BT57-1),
PCR amplification of reporter
DNA attached to antibody
219
Chemiluminescent
slot blot
immunoassay
6 h E 4 MLD Bacterial cultures, inoculated
fish, naturally
contaminated soil
Polyclonal (rabbit) Ab,
chemiluminescent detection of
slot-blotted culture
supernatant
32
Electro
chemiluminescence
1–3 h B 1–2 ng/ml Purified toxin Monoclonal (B 2/3) and
polyclonal (horse) Ab,
immunomagnetic
concentration
87
Radioimmunoassay 8 h A 100 MLD50 Purified toxin Polyclonal (rabbit) Ab 23
Lateral flow
immunoassays
15–30 min A, B, E 15 pg–10 ng/ml Inoculated milk products Immunochromatographic
detectiond
187
20 min A 15–150 pg/ml Vegetables and seafood Ganglioside-liposome (GTb1) as
CA, immunological detection
1
Endopeptidase assay 8 h A 0.1–0.8 MLD50 Toxin potency testing in the
medical industry
Peptide substrate specific for
SNAP-25e, immunological
detection
59
5–6 h B 5–10 pg/ml Inoculated meat pate, cheese,
cod, mince, sausages
Immunoconcentration of toxin
with monoclonal antibodies,
peptide substrate specific for
VAMP f, immunological
detection
215, 216
8 h A, B 0.1–4.5 ng/ml Bacterial cultures Peptide substrates specific for
VAMP/SNAP-25,
immunological detection
89
8 h A, B, D, F 2 ng/ml Toxin potency testing in the
medical industry
Fluorigenic peptide substrates
specific for VAMP/SNAP-25
182
8 h A, B, E, F 0.04–0.6
MLD50/ml
Purified toxins Peptide substrates specific for
VAMP/SNAP-25, multiplex
detection with mass
spectrometry
26
a Ab, antibody; CA, capture antigen.
b In 98% of cases a positive result is observed in 24 h (39).
c NR, not reported.
d The type of antibody was not reported.
e SNAP-25, 25-kDa synaptosomal-associated protein.
f VAMP, vesicle-associated membrane protein.
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tend to interfere with the ELISA, decreasing the test sensitiv-
ity, but successful ELISA detection of botulinum toxins at least
in fish fillets (178), canned salmon and corned beef (189),
turkey meat (174), mascarpone cheese (66), pasta products
(46), potatoes (68), chili (67), and canned beans and mush-
rooms (177) has been reported. The limitations of each assay
should be borne in mind; for example, the ELISA-ELCA that
employs chicken and biotinylated antibodies is not suitable for
investigation of foods containing chicken meat, egg yolk, egg
white, and milk (54, 188).
Reports on the performance of ELISAs on clinical speci-
mens such as serum (173) and feces (49) are limited (Table 2).
Fecal extracts have been shown to drastically interfere with the
ELISA reaction, decreasing its sensitivity (49). In a study on 22
cases of infant botulism, the performance of the ELISA was
improved using extended incubation times and fetal bovine
serum to block the interfering fecal substances, and the test
proved to be even more reliable than the mouse assay, which
produced some false-positive results (49). An ELISA-ELCA
was suggested to perform well with complex clinical matrices
such as blood and excreta (54), but to our knowledge, no
reports on the systematic validation of any ELISA procedures
for the detection of botulinum toxin in clinical materials have
been published. However, as the ELISA procedures can be
finished within a working day, they would be suitable for initial
screening in suspected cases of botulism (Fig. 1).
A chemiluminescence immunoassay for type E toxin, com-
bined with a slot blot transfer of culture supernatants into a
polyvinylidene fluoride membrane, was reported to be even
faster to perform than ELISA and possessed a relatively high
sensitivity (32). However, false-positive results were obtained
with inoculated fish samples (32). The detection limit of an
electrochemiluminescence assay employing an immunomag-
netic concentration of target antigen is similar to that of the
mouse bioassay (87). The electrochemiluminescence technol-
ogy seems to be a promising alternative for the detection of
botulinum toxins, but like many of the recent advances in toxin
detection, it requires further testing with complex matrices.
Commercial lateral flow assays in a dipstick form would
provide convenience in toxin testing, as they are easy and rapid
(30 min) to perform and no additional equipment is re-
quired. However, the speed backfires in terms of the sensitivity
of many lateral flow tests, and their usefulness may thus prove
to be limited (104, 187) (Table 2). An assay employing the
receptor for botulinum neurotoxins, trisialoganglioside GT1b,
as a capture agent was shown to provide a sensitivity similar to
that of the mouse assay with type A toxin, but fatty foods were
reported to interfere with the test (1). Lateral flow assays may
serve as efficient and valuable initial screening tools in sus-
pected cases of botulism, but negative results particularly
should be confirmed with the mouse bioassay. Attention
should also be paid to the optimization of sample pretreatment
to avoid false-negative results due to interference by the sam-
ple matrix (187).
Endopeptidase assays. The property of the botulinum neu-
rotoxin of having a highly specific zinc-endopeptidase activity
with selected targets in the synaptic cleft has inspired the
development of in vitro assays for toxin detection. The endo-
peptidase assays are based on specific cleavage of synaptic
proteins (SNARE complex proteins) by different botulinum
neurotoxins, combined with immunological detection of the
cleaved peptide (89, 216), or detection of fluorescence released
when a peptide labeled with a quenched chromophore is
cleaved (182).
Endopeptidase assay formats for types A (59, 89, 182), B (89,
182, 215, 216), D (182), E (T. Ekong, J. W. Austin, J. P. Smith,
I. Dufresne, and M. Brett, Abstr. Interagency Botulism Res.
Coord. Committee Meet., Orlando, Fla., p. 36, 1999), and F
(182) have been described, but commercial solutions are avail-
able only for type A toxin detection. The endopeptidase assays
have potential to replace the mouse lethality assay, as they
detect only biologically active neurotoxin and are generally
more sensitive than the mouse assay (26, 65, 216). Detection of
the cleaved peptide by mass spectrometry further increases the
sensitivity (26), but due to the requirement of expensive equip-
ment and specialized skills, the technique is not suitable for
every laboratory. The highest sensitivity, 200-fold compared to
that of the mouse assay, has been obtained with surface plas-
mon resonance spectroscopy detection of the cleavage of na-
tive SNARE complex proteins by botulinum toxin types B and
F in rat brain synaptic vesicles (65). This method was also
assumed to be compatible with complex matrices such as se-
rum and foods; however, its use for this purpose was not
reported (65).
The endopeptidase assays are highly specific, and no cross-
reactivity between different botulinum toxins or with tetanus
toxin has been reported. Functional assays based on immuno-
logical detection have been successfully used to detect botuli-
num toxin type B in various foods, such as pate´, cod, and
cheese (215, 216). The interference of the assay by fatty foods
was avoided by immunological concentration of the neurotoxin
using monoclonal antibodies against the type B toxin prior to
the endopeptidase assay. However, false-negative results were
obtained due to the inability of the monoclonal antibodies to
recognize all type B toxins produced by different C. botulinum
strains (215).
More research is needed to validate these assays for all toxin
types and, particularly, with complex matrices such as feces and
foods that may contain endogenous proteinases. Also, sub-
stances such as EDTA, which is used as a common plasma
anticoagulant in blood sample tubes, have been shown to in-
hibit the assay for type A toxin (59).
Culture Methods for Clostridium botulinum
C. botulinum requires strict anaerobic conditions for growth.
This creates challenges for laboratory work with the organism.
All culture media must be deoxygenated by heating in a boiling
water bath or by a continuous flow of an anaerobic gas mixture.
Reducing agents, such as thioglycolate, may be added in media
to maintain anaerobiosis during culture and incubation. The
use of appropriate oxygen indicators in culture media as well as
in anaerobic jars and anaerobic workstations is part of the daily
routine in a C. botulinum laboratory. All glassware and plastic
supplies, such as containers, tubes, and pipette tips, should be
deoxygenated before contact with C. botulinum cultures. Con-
tinuous work in an anaerobic workstation is a necessity for
successful diagnostics.
The species C. botulinum consists of physiologically distinct
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organisms (Table 1), which hampers the development of diag-
nostics. Conventional detection and isolation of C. botulinum
are based on culturing in liquid medium and subsequent de-
tection of botulinum toxin in the culture supernatant by the
mouse bioassay (118). Positive samples are streaked on solid
media, and the toxin formation by colonies is traditionally
further confirmed by the mouse test. Clinical samples, such as
serum and feces, can be cultivated directly or pretreated with
ethanol to eliminate vegetative bacteria while recovering bac-
terial spores (163). Heating may alternatively be used to elim-
inate nonsporeformers, but care should be taken in selecting
the temperature; 80°C for 10 min has been recommended for
group I spores, but this temperature may injure group II spores
(197). Heating at 60°C for 10 to 20 min is thus a safer choice
for group II spores. The addition of a heat-resistant lytic en-
zyme, such as lysozyme (5 g/ml), to the culture medium may
enhance germination of heat-stressed spores (169, 170).
Routine liquid media include chopped-meat–glucose–starch
medium (39); cooked-meat medium (175, 176); broths contain-
ing various combinations of tryptone, peptone, glucose, yeast
extract, and trypsin (e.g., tryptone-peptone-glucose-yeast ex-
tract medium) (129); reinforced clostridial medium (79); and
fastidious anaerobe broth (179). All of these media are non-
selective and thus allow the growth of a range of other bacteria.
Blood agar and egg yolk agar (EYA) (94) serve as the most
common unselective plating media, with EYA enabling the
lipase reaction typical of C. botulinum (Table 1). However,
many other clostridia produce lipase and may therefore con-
fuse the identification (35). EYA medium alone does not con-
tain any inhibitory compounds, but when supplemented with
cycloserine, sulfamethoxazole, and trimethoprim, EYA-based
selective media (e.g., C. botulinum isolation medium) have
been reported to select group I C. botulinum (50, 153, 190).
These media have been successfully used in the investigation of
fecal samples in cases of infant botulism (48, 50, 82). However,
as these media may suppress the growth of group II C. botu-
linum (214), their value in the diagnostics of food-borne bot-
ulism is limited.
The identification of botulinum toxin in and around C. bot-
ulinum colonies grown on agar plates would facilitate the iden-
tification and isolation of C. botulinum and neurotoxin-produc-
ing C. butyricum and C. baratii among competitive microflora.
Procedures based on immunodiffusion (69, 152, 190, 210) or
immunoblotting (83) have been published. As a single C. bot-
ulinum colony may produce as much as 105 minimal lethal
doses (MLD) of toxin within 24 h (69), the colony immunoblot
assay, which detects 10 to 25 50% MLD (MLD50) of toxin per
spot (83), would be sufficiently sensitive for the identification
of C. botulinum on an agar plate. No reports on the perfor-
mance of these tests with naturally contaminated clinical or
food samples or mixed bacterial populations have been pub-
lished. Fluorescent antibodies against the cell walls of vegeta-
tive C. botulinum have also been used to identify C. botulinum
in a culture (81), but this method suffers from cross-reactivity
between C. botulinum and its nontoxingenic counterparts.
A dilemma arising from the different physiologies of group I
and II strains is the selection of the correct incubation tem-
perature (Table 1). Group I strains grow optimally at 35 to
37°C, whereas group II strains favor lower temperatures of 25
to 30°C (197). If both groups are being sought in a single
sample, a compromise of 30°C has been proposed (197). How-
ever, investigating replicate samples at 26 to 30°C and at 35 to
37°C is preferable to ensure optimal growth for both groups.
The optimal incubation time varies with the sample material
and the detection method selected to identify the presence of
C. botulinum in the culture tube. When the mouse bioassay is
used to identify toxin formation in culture tubes, an incubation
period of 5 to 7 days has been recommended (197). Shorter
incubations may become relevant if molecular biological tech-
niques, such as PCR (see below), are employed (133).
As the prevalence of C. botulinum in naturally contami-
nated samples is generally relatively low (10 to 1,000 spores/
kg) and as there are no proper selective media available,
quantification of C. botulinum in samples containing other
bacteria by use of plate count procedures is difficult, if not
impossible. Therefore procedures for enrichment in liquid
media are often needed. In such cases the quantification of
the organism is obtained with a most-probable-number tech-
nique. The most-probable-number estimate is based on the
amount of sample material containing the target organism
and the total amount of sample material investigated. In
general, the greater the number of culture tubes that are
used, the more accurate is the estimate obtained. The pres-
ence of C. botulinum in the culture tubes can be determined,
e.g., with the mouse bioassay or by PCR (98).
As the group I and II strains differ in their epidemiologies,
discrimination between the two groups should be done when-
ever an outbreak strain is isolated (Fig. 1). To be able to
distinguish between the two groups, the proteolytic activity of
group I strains can be determined on a casein-containing agar,
e.g., reinforced clostridial medium supplemented with milk
(169). Alternatively, molecular biological techniques such as
probe hybridization or ribotyping (see below) can be em-
ployed. Although group I and II C. botulinum strains are dis-
similar in many respects, both are able to grow at an incubation
temperature range of 30 to 37°C, which is often used. There-
fore, the ability to grow at a certain temperature should not be
used as a feature determining the physiological group of a C.
botulinum isolate.
Commercial test systems based on series of biochemical
reactions have been developed for the identification of anaer-
obic bacteria. Contradictory reports on the ability of these tests
to identify Clostridium spp. are available; different tests have
been able to correctly identify 54% to 96% of the clostridial
strains studied to the species level (31, 85, 95, 141). Due to the
diverse physiology of C. botulinum, not all strains can be iden-
tified to the species level (28, 132). The biochemical test sys-
tems are also susceptible to technical bias, and factors such as
incubation environment (171), incubation time (85), and con-
centration of the cell suspension (28) have been reported to
drastically affect the success of identification.
For the reasons discussed above, the identification and iso-
lation of C. botulinum from samples with high levels of com-
petitive bacterial flora, such as fecal and environmental sam-
ples, are laborious and time-consuming. Several subsequent
broth cultures and platings are required to isolate a pure cul-
ture, and often the isolation simply fails. The presence of
nontoxigenic C. botulinum-like strains (30, 127, 132) disturbs
the culture of C. botulinum. Whether these strains are com-
pletely different bacterial species from C. botulinum or whether
VOL. 19, 2006 LABORATORY DIAGNOSTICS OF BOTULISM 305
they derive from toxigenic C. botulinum (221) by complete or
partial deletion of the toxin gene cluster during the exhaustive
subculture procedures warrants further investigation. In botu-
lism cases due to type E and F toxins, the possibility of toxin-
producing C. butyricum or C. baratii causing botulism should
not be ignored unless C. botulinum can be identified. These
bacteria differ physiologically from C. botulinum strains (35),
and the laboratory routines established for C. botulinum are
not directly applicable for the isolation and identification of
these species.
Molecular Detection of Clostridium botulinum
DNA-based detection methods have overtaken conventional
techniques, with numerous molecular detection protocols pub-
lished for C. botulinum (Table 3). Ascendant techniques in-
clude PCR and Southern hybridization, both of which are
sensitive and specific and are rapid compared to culture tech-
niques and the mouse bioassay. Many laboratories have al-
ready invested in PCR thermocyclers and electrophoresis
equipment, and their staff are experienced with molecular
TABLE 3. PCR and probe hybridization protocols applied for the detection and identification of Clostridium botulinum groups I and II in
different types of samples
Sample type and pretreatment Assay type Toxin types detected Sensitivity Reference(s)
Extracted DNA from pure cultures PCR  gel electrophoresis A, B, E, F 0.3 ng 42
PCR  gel electrophoresis A, B, C, D, E, F 2.5 pg 207
PCR  probe hybridization A 12.5 fg 62
Real-time PCR A, B, E 42–195 fg 2
Real-time PCR A 0.1 ng 223
Multiplex PCR  hybridization
onto array
A, B, E, F 0.015–0.5 pg 78
Extracted DNA from spores
inoculated in foods
Real-time PCR A 102–103 spores/ml 223
Extracted DNA from PCR  probe hybridization A, B, E, F 0.1 cell/g 8
enriched foods PCR  probe hybridization A, B, E, F, G 10 cells/g 61
PCR  probe hybridization A, B, E 0.1–21 spores/g 27
PCR  capillary
electrophoresis
E 10 cells 183
Extracted DNA from enriched
foods, environmental samples,
and clinical samples
PCR  gel electrophoresis A, B, E 102 spores/g 205
Extracted DNA from
enriched feces
Nested PCR  gel
electrophoresis
B NRa 117
Extracted DNA from enriched
foods and environmental
samples
PCR-ELISA A, B, E, F 101 cell/g 63
Extracted DNA from heated and
enriched feces
Nested PCR  gel
electrophoresis
B, E, F 10–103 spores/g 43, 44
Extracted DNA from foods
and feces
Real-time PCR A, B, E NR 2
Extracted DNA from foods Multiplex PCR  gel
electrophoresis
A, B, E, F NR Wyatt et al., Abstr.
Rapid Methods
2005
Extracted DNA from wound
swabs, tissues, pus
Real-time PCR A, B, E 10–102 cells 3
Crude cell lysate from PCR  probe hybridization A, B, E NR 73
enrichment broth Multiplex PCR  gel
electrophoresis
A, B, E, F 10–102 cells 133
Multiplex PCR  hybridization
onto array
A, B, E, F 4  102 cells 78
Crude cell lysate from
enriched foods
PCR  probe hybridization A 10–103 cells/g 62
Crude cell lysate from enriched
foods and feces
Multiplex PCR  gel
electrophoresis
A, B, E, F Food, 102–101
spore/g; feces,
101–103 spores/g
133
a NR, not reported.
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techniques. In the case of C. botulinum, molecular detection
techniques are based merely on the detection of the botulinum
neurotoxin gene, bot, in the sample, and thus they do not
detect the activity of the gene nor the toxin. Naturally this is a
disadvantage, but, apart from the advantages mentioned
above, molecular techniques do not require the use of labora-
tory animals. This makes them a suitable tool for screening
bacterial colonies, pure liquid cultures, and sample enrich-
ments for the presence of the neurotoxin genes, indicating the
presence of C. botulinum and other toxin-producing clostridia.
Most reports on PCR detection of C. botulinum are based on
a single detection of one of the seven types of toxin genes in a
reaction (Table 3). An improvement has been the development
of a multiplex PCR assay that enables the simultaneous detec-
tion of the botA, botB, botE, and botF genes in a single reaction
(133). This significantly decreases the assay time and labor and
naturally the reagent costs. The multiplex PCR products are
detected using conventional gel electrophoresis (133) or by
further hybridization onto a membrane coated with cDNA
probes to the PCR products (78). The two methods provide
similar sensitivities (Table 3).
As both the botB and botF genes of group I and II C.
botulinum are highly similar, the molecular detection methods
based on these neurotoxin genes do not reveal the physiolog-
ical group of C. botulinum. An oligonucleotide probe specific
for the 23S rRNA gene specifically detects group II strains
(33), but as this probe also recognizes the nontoxigenic C.
botulinum-like strains within group II, its value as the only
diagnostic tool is limited. A HindIII fragment-based DNA
probe specific for group I C. botulinum would better suit the
purpose, as it does not hybridize to C. sporogenes (147). Some
molecular typing methods such as ribotyping and amplified
fragment length polymorphism (AFLP) (see below) are also
suitable for differentiation between C. botulinum groups I and
II (97, 120).
The sensitivities of the PCR and probe hybridization assays
reported for the detection of C. botulinum in feces, serum, and
food samples vary markedly (Table 3). Greater sensitivity is
generally obtained when extracted DNA, as opposed to crude
cell lysates, is used as a template. The DNA extraction proce-
dures applied for C. botulinum, however, may be laborious and
time-consuming (109, 120, 142), while a cell lysate is easily
prepared in an hour (73).
The sensitivity of PCR can also be increased by a nested
design, where two primer sets targeted to the same gene are
used in subsequent reactions. Nested PCR protocols have been
published for the botB, botE, and botF genes (43, 117). The
nested PCR format may allow the shortening (43) or complete
exclusion of enrichment steps that are often required with
normal PCR. C. botulinum type B was successfully detected
directly from feces of an infant botulism case when using a
nested PCR format (117). However, the detection limit of the
assay was not determined, and this should ideally be done
before the method can be reliably applied in diagnostics.
Some components in clinical and food samples, such as bile
salts or competitive microflora in feces, immunoglobulins, and
other components in blood and high protein and fat contents
in foods, may inhibit PCR or at least drastically decrease its
sensitivity (4, 5, 124). For example, the PCR detection limit for
C. botulinum type E in feces was shown to be 4 log units higher
than that in a fish or meat matrix (133). This should be borne
in mind when setting up PCR protocols for clinical specimens.
Each type of sample material requires thorough optimization
of PCR as well as prior sample preparation. Sample pretreat-
ment should focus on concentrating target cells and eliminat-
ing competitive flora and PCR-inhibitory substances. Internal
amplification controls as well as other appropriate control set-
ups should be routinely used in diagnostic PCR to control
inhibition by the sample material or contamination (102, 103).
Reports on their use in the molecular diagnostics of C. botu-
linum are so far scarce (63; G. M. Wyatt, J. Plowman, C. F.
Aldus, M. W. Peck, and W. Penaloza, Abstr. Rapid Methods
2005, Noordwijk, The Netherlands, p. 8, 2005).
As the number of C. botulinum organisms in naturally con-
taminated samples is often very low and the target organism
forms resistant spores, PCR detection directly from sample
materials may often fail due to insufficient sensitivity of the
assay. Enrichment is thus required to germinate spores and
increase the target cell concentration in the sample (Table 3).
Again, when investigating samples where both group I and
group II C. botulinum may be present, careful consideration of
enrichment conditions is urged, and optimally replicate sam-
ples will be incubated both at 35 to 37°C (for group I) and at
26 to 30°C (for group II). The duration of the enrichment step
for optimal performance of PCR is also an important issue and
should always be determined for each sample material (133)
and enrichment medium. Too short an enrichment may result
in competitive bacteria overtaking C. botulinum, whereas ex-
tensive incubation may result in lysis or sporulation of C. bot-
ulinum cells. Ideally PCR is done from a culture on several
subsequent days to determine the optimal length of enrich-
ment for each type of sample (133).
Another problem of direct PCR analysis from sample ma-
terial is the possible detection of dead cells due to intact DNA
after cell lysis (218). Enrichment procedures partly solve the
problem by increasing the number of live cells in proportion to
dead cells (98). Another approach to ensure that only live cells
are detected is reverse-transcription PCR (RT-PCR), where
gene expression rather than the gene itself is detected. Reverse
transcription-PCR protocols for the botB and botE genes have
been described (136, 137, 146). In a case of a human botulism
outbreak, however, laborious procedures to obtain high-quality
RNA may prove to be too time-consuming.
The different chemistry (intercalating fluorescent dyes or
probes with a quencher dye) of real-time PCR from that of
conventional PCR allows real-time monitoring of the amplifi-
cation of the target gene after each PCR cycle, enabling rapid
interpretation of results. In some experimental settings the
melting temperature of the amplicons also can be calculated,
which is essential to differentiate the specific PCR product
from unspecific amplicons. Real-time PCR has been applied
in the qualitative detection of C. botulinum types A, B, and
E in foods and feces from food-borne and infant botulism
cases (2). The same PCR protocol was recently employed in
investigation of tissue, wound swab, pus, and aspirate sam-
ples from cases of wound botulism (3). When subjected
directly to DNA extraction and PCR, only a small number of
tissue samples from two patients were positive in the real-
time PCR analysis. PCR inhibition was suggested to explain
some of the negative results; however, after a 1- to 5-day
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enrichment in liquid medium, most samples from patients
with toxin detected in their sera were shown to carry one or
more neurotoxin genes (3).
Apart from rapidity, another advantage of real-time PCR is
its ability to quantify the target sequence, reflecting the level
of the organism. To obtain reliable quantification, the copy
number of the target gene in the genome of the organism in
question must be known. Furthermore, the requirements for
selection of reagents, reaction standardization, and sample
pretreatment are higher than those for conventional PCR.
Quantitative detection of the botB gene has been employed for
research purposes (136, 137), whereas a recent application
allowed the quantitative detection of C. botulinum type A
spores spiked in canned corn and sausage (223) (Table 3). In
this method, DNA is extracted directly from spores and no
enrichment steps are employed. This allows the whole analysis
to be finished within a working day. However, the speed is
achieved at the cost of sensitivity; no fewer than 100 spores are
detected (223). As the natural contamination levels of C. bot-
ulinum in food, clinical, and environmental samples may be 10
to 1,000 spores/kg, it is obvious that enrichment steps are
needed for successful detection.
As discussed above, C. botulinum strains carrying silent toxin
genes may confuse PCR detection by causing false-positive
results (73). Conversely, point mutations or natural genetic
variation in the template at the site of one or both PCR
primers may impair primer annealing, thus causing false-neg-
ative results even if the gene is present and fully functional
(Wyatt et al., Abstr. Rapid Methods 2005). Hence, although
PCR can be a powerful screening tool in the laboratory diag-
nostics of botulism outbreaks, the results should ideally be
confirmed by other methods. The specificity of PCR should
be confirmed by combining PCR with bot gene-specific probe
hybridization or by DNA sequencing of the PCR product in-
stead of or in addition to plain fragment size-based gel elec-
trophoresis analysis. Relying merely on PCR results is some-
what risky and should ideally be avoided if possible. It should
also be borne in mind that PCR does not detect botulinum
neurotoxin.
Genetic Characterization of Clostridium botulinum
A number of molecular typing tools have been used for the
genetic characterization of C. botulinum. These include DNA
sequencing, pulsed-field gel electrophoresis (PFGE), and ribo-
typing, as well as PCR-based techniques such as AFLP, ran-
domly amplified polymorphic DNA analysis (RAPD), and re-
petitive element sequence-based PCR (Rep-PCR) (Table 4).
International molecular typing libraries with genetic finger-
prints, preferably obtained by use of more than one technique,
of C. botulinum strains isolated in botulism epidemics would
serve as a valuable source of information when investigating
new outbreaks. As the modern food industry focuses on long
shelf lives and refrigerated storage, product delivery routes
may be long and the same product may be transported to many
different countries. It is therefore likely that botulism out-
breaks, instead of being sporadic and restricted to a limited
geographic area, will be distributed over a wide area and thus
be difficult to solve (122).
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Pulsed-field gel electrophoresis. Macrorestriction pattern
analysis by PFGE has become one of the most powerful ge-
netic typing tools in the diagnostics of food-borne pathogenic
bacteria. The method is based on the electrophoresis of
genomic DNA digested with rare-cutting restriction enzymes,
yielding a distinctive fingerprint pattern for each bacterial
strain. These fingerprints consist of 5 to 15 fragments in the
size range of 10 to 1,000 kbp. In the diagnostics of botulism,
PFGE can be used to trace the source of outbreaks by genetic
comparison of C. botulinum isolates originating from patients
and suspected food items (113, 131, 161). PFGE has also been
used to study the biodiversity of C. botulinum (96, 110, 160).
The first report on PFGE for genotyping of C. botulinum was
targeted to group I A toxin-producing strains and used MluI,
RsrII, and SmaI restriction enzymes (130). Three different
strains gave a distinctive PFGE pattern, whereas different iso-
lates of the same strain gave similar PFGE patterns. A recent,
more extensive study on PFGE typing of C. botulinum group I
recommended the use of SacII alone or in combination with
SmaI and XhoI (160). Analysis of 55 group I type A, B, AB,
and F organisms revealed a high similarity among types AB
and B and among type F organisms (160). For C. botulinum
group II, PFGE using XhoI and SmaI proved to be highly
discriminative, yielding a large genetic diversity among strains
isolated from aquatic environments (96, 110).
Although reproducible and discriminative, PFGE analysis is
laborious and takes several days to complete. A further disad-
vantage is that the method is sensitive to DNA degradation by
extracellular DNases, and not all strains, particularly group II
strains, are typeable with standard procedures. Cell fixation
with formaldehyde treatment has solved this problem in most
cases (95) (Table 4).
Ribotyping. The conservative ribosomal genes (rRNA genes)
have become the most widely researched targets for phyloge-
netic analysis of organisms. One application is bacterial rRNA
gene restriction pattern analysis (ribotyping), which is based on
a genomic restriction pattern hybridized with labeled cDNA
probes targeted to Escherichia coli rRNA genes (86). Possess-
ing a lower discriminatory power than PFGE in bacterial
strain-to-strain differentiation but a sufficiently high power to
discriminate between bacterial species makes ribotyping an
ideal tool for phylogenetic analysis. The method has effectively
discriminated between 8 C. botulinum group I and 19 group II
strains with EcoRI (97), confirming that the two groups belong
to distinct phylogenetic lineages (41). Ribotyping is highly re-
producible, but as with PFGE, degradation of DNA may
hinder the typing of some strains (97) (Table 4). A good indi-
cation of the strong position of ribotyping in today’s phyloge-
netic analysis is RiboPrinter, an automated ribotyping system
(Qualicon, Wilmington, DE) that has also been used for C.
botulinum (191).
Amplified fragment length polymorphism. The AFLP tech-
nique is a relatively new genetic typing tool that is based on
digestion of genomic DNA with two restriction enzymes, fol-
lowed by ligation of restriction site-specific adapters and am-
plification of a subset of fragments by PCR (212). An AFLP
analysis of 33 group I and 37 group II C. botulinum strains with
HindIII and HpyCH4IV revealed that the method is fast,
highly reproducible and discriminative, and an excellent typing
tool for C. botulinum (120). The same study also showed that
AFLP, like ribotyping, is well suited to phylogenetic analysis
and satisfactorily discriminates between group I and group II
strains. Furthermore, AFLP is not disturbed by DNA degra-
dation, so it provides 100% typeability (Table 4).
Randomly amplified polymorphic DNA analysis. Also re-
ferred to as arbitrarily primed PCR, RAPD is based on PCR
with randomly annealing universal primers under low-strin-
gency conditions (217). It is fast and easy to perform, and the
protocol applied for group II C. botulinum has been reported
to be even more discriminatory than PFGE (109). The discrim-
inatory power was lower with group I strains. All strains are
typeable with RAPD. However, due to the random annealing
of unspecific primers, the method lacks sufficient reproducibil-
ity and is thus not well suited for interlaboratory comparison of
bacterial strains (Table 4).
Repetitive element sequence-based PCR. Bacterial genomes
harbor conservative repetitive extragenic elements that can
be used as targets for PCR with single or multiple consensus
primers (211). The number and size of amplification products
define a species-specific fingerprint; however, differentiation
to the strain level is limited, restricting the applicability of
the method in epidemiological and clinical research. A Rep-
PCR protocol established for C. botulinum allowed the
group II type B and E toxin-producing strains to be differ-
entiated to the strain level, whereas the group II type F
toxin-producing strains and all group I strains were differ-
entiated only to the toxinotype level (109). A group-specific
amplification fragment was obtained for both groups, sug-
gesting that the method could be used for determining the
physiological group of disease isolates in botulism cases.
Like RAPD, Rep-PCR is rapid to perform; the advantage of
Rep-PCR over RAPD is its higher reproducibility due to the
use of specific primers (Table 4).
The findings obtained with the different genetic typing tools
described above suggest that group I and II strains may have
different epidemiological behavior in the environment, result-
ing in a narrower diversity of group I strains than of group II.
This might be due to different bacterial life cycles in soil and
water; aquatic environments may provide more optimal con-
ditions for frequent spore germination than soil, leading to
greater genetic variation in organisms of aquatic origin, such as
group II C. botulinum. Whether this is true or whether the
current typing tools are just insufficiently discriminatory with
group I strains warrants further investigation.
FUTURE PERSPECTIVES
While there has been tremendous progress in the develop-
ment of in vitro tests to potentially replace the mouse assay in
the detection of botulinum neurotoxins and molecular biolog-
ical tools for the detection and characterization of C. botuli-
num, far more needs to be done. The in vitro toxin tests need
further rapidity and sensitivity in a single test, and all seven
toxin types should ideally be identified simultaneously. Fur-
thermore, the tests should be validated with a range of complex
matrices, such as feces, foods, and environmental samples, in
addition to testing with purified toxins.
Although the molecular biological methods for the detection
and identification of C. botulinum are promising, the conven-
tional culture techniques should not be overlooked. Selective
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media suitable for both group I and II C. botulinum and other
toxin-producing clostridia are needed to harvest all possible
toxin-producing strains from sample materials containing com-
petitive bacteria. As the distinct physiologies of the different
groups of C. botulinum apparently complicate the detection
and isolation procedures, the taxonomy of the species should
be reconsidered to correspond to the true genetic variation
among the botulinum neurotoxin-producing strains.
Whereas the main goal of the laboratory diagnostics of bot-
ulism is to achieve a rapid diagnosis and to save the patient,
appropriate laboratory procedures should aim at a more thor-
ough understanding of the epidemiology of, risk factors for,
and prevention of botulism due to either of the two groups of
C. botulinum. The isolation and genetic characterization of C.
botulinum originally from the patient and the source should be
done whenever possible (Fig. 1).
Bacterial genome sequencing has created new possibilities in
genetic typing as well as in researching the genetic mechanisms
behind different metabolic traits such as neurotoxin formation
and its regulation. DNA microarrays enable genome-wide
analysis of microorganisms and will probably overtake the
more conventional genetic typing tools within a few years.
While bacterial genomes are being sequenced at an increasing
speed, more genomic information about closely related species
and bacterial strains is needed. The genome of a group I C.
botulinum strain (type A, ATCC 3502) has been elucidated
(Sanger Institute, Cambridge, United Kingdom), enabling the
development of a C. botulinum microarray (http://pfgrc.tigr.org
/organisms.shtml). However, due to differences between group
I and II organisms, the applicability of the type A array in
genomic analysis of group II organisms may prove to be lim-
ited. Attempts to sequence a group II C. botulinum genome are
therefore necessary. Naturally, genomic information on a sin-
gle strain will not provide a good overall understanding of the
genetic diversity within the species. Thus, additional research
funding allocated to C. botulinum genome sequencing projects
is needed to shed light on the genetic diversity and the mech-
anisms underlying different metabolic phenomena among bot-
ulinum neurotoxin-producing clostridia.
CONCLUSIONS
As botulism is a potentially lethal disease, a rapid diagnosis
is essential. Active research on assay development is thus re-
quired. In vitro assays for rapid and sensitive detection of all
types of botulinum toxin are needed, as are thorough valida-
tions of these tests with a range of complex matrices. In the
meantime, molecular biological detection and identification
tools should be used in screening and surveillance whenever
possible to diminish the use of the mouse bioassay. More
sophisticated and efficient tools to isolate group I and II strains
from clinical, food, and environmental sample materials are
needed. To enhance the development of culture methods for
group I and II (and III) C. botulinum, the taxonomy of the
organism should be reconsidered to correspond to the true
genetic variation among the botulinum neurotoxin-producing
bacteria.
Whereas the rapid laboratory diagnosis of botulism is based
on detection of toxin in the patient, a thorough epidemiolog-
ical investigation of botulism outbreaks and the causative or-
ganism is needed to increase our understanding of the different
forms of the disease and their prevention. The laboratory di-
agnostics of each case of human botulism should include every
attempt to isolate C. botulinum from the patient as well as from
the source. In addition to the identification of the toxin type
that they produce, these isolates should be typed to reveal the
physiological group of C. botulinum. Genetic characterization
of the isolates should be included in routine diagnostics and
epidemiological investigation (Fig. 1).
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